Charles River Laboratories International Q1 Earnings Call Highlights
Key takeaways
- Charles River beat its prior outlook in Q1 2026, with revenue of $996 million up 1.2% year over year, though organic revenue fell 1.5% and non-GAAP EPS declined 12% to $2.06.
- The company reaffirmed full-year 2026 guidance for organic revenue down 0.5% to 1.5% and non-GAAP EPS of $10.80 to $11.30, while still expecting 120 to 150 basis points of margin expansion later in the year.
- Portfolio reshaping and new CEO strategy are major themes, as Birgit Girshick launched the “Pathway to Purpose” plan and the company completed or advanced several divestitures and acquisitions.
Charles River Laboratories International Q1 Earnings Call Highlights Market Beat Sun, May 10, 2026 at 6:03 AM GMT+7 8 min read CRL DX-Y.NYB Charles River Laboratories International logo Key Points Interested in Charles River Laboratories International, Inc.? Here are five stocks we like better.
Charles River beat its prior outlook in Q1 2026, with revenue of $996 million up 1.2% year over year, though organic revenue fell 1.5% and non-GAAP EPS declined 12% to $2.06. Management said results were slightly ahead of expectations despite margin pressure from NHP costs, stock compensation tied to the CEO transition, and mix issues.
The company reaffirmed full-year 2026 guidance for organic revenue down 0.5% to 1.5% and non-GAAP EPS of $10.80 to $11.30, while still expecting 120 to 150 basis points of margin expansion later in the year. Charles River also increased its reported revenue decline outlook because of a stronger U.S. dollar.